Do you want to read an article? Please log in or register.
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
Gynecologic Cancer
Related content
COMMENTED
Breast Cancer
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer
★ 0
Recommended and commented by
Dr Andreas Müller, Faculty Member
Clin Breast Cancer
Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK)
doi: 10.1016/j.clbc.2025.05.015
Breast Cancer
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
Ann Oncol
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D
doi: 10.1016/j.annonc.2024.10.015
Genitourinary Cancer
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K
doi: 10.1016/S0140-6736(25)00684-1
Gastrointestinal Cancer
Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III randomized controlled trials
Eur J Cancer
Akkus E, Lamarca A
doi: 10.1016/j.ejca.2025.115342
Head and Neck Cancer
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial
Exp Hematol Oncol
Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N
doi: 10.1186/s40164-025-00703-x
Genitourinary Cancer
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N
doi: 10.1016/S0140-6736(25)00683-X
Gastrointestinal Cancer
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
J Clin Oncol
Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Tran Q, Cremolini C, Fakih M
doi: 10.1200/JCO-24-02026
Gynecologic Cancer
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
Ann Oncol
Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ, Leiva M, Cetina-Pérez LDC, Varga S, Molina Alavez A, Alarcon-Rozas AE, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Shapira-Frommer R, Estevez-Diz MDP, Limaye S, Xin W, Dry H, Broggi MAS, Yuan DY, Stewart RA, Monk BJ
doi: 10.1016/j.annonc.2025.05.533
Genitourinary Cancer
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
Ann Oncol
Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Fleming M, Haas T, Ghebremariam S, Kreisl TN, Rajagopalan S, Sartor O, Morris MJ, PSMAfore Investigators
doi: 10.1016/j.annonc.2025.07.003